Fibrous Dosage Form EP3500242A1
Summary
The European Patent Office published patent application EP3500242A1 titled 'Fibrous Dosage Form' on April 8, 2026. The patent application, filed by applicant Aron H. Blaesi with inventors Blaesi and Nannaji Saka, covers pharmaceutical dosage formulations classified under IPC A61K. The application designates multiple European member states for patent protection.
What changed
The European Patent Office published patent application EP3500242A1 for a fibrous dosage form formulation. The application covers pharmaceutical preparations including solid dosage forms classified under IPC codes A61K 9/00, 9/16, 9/20, and various active pharmaceutical ingredients including compounds classified under A61K 31/167 and A61K 31/192.
For pharmaceutical manufacturers developing oral dosage forms, this published application establishes prior art that may affect freedom-to-operate for similar fibrous or solid oral formulations. Companies should monitor the patent prosecution for scope and potential blocking positions in European markets including Germany, France, the UK, Italy, Spain, and other designated states.
What to do next
- Monitor patent register for grant status
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FIBROUS DOSAGE FORM
Publication EP3500242A1 Kind: A1 Apr 08, 2026
Applicants
Blaesi, Aron H.
Inventors
BLAESI, Aron, H., SAKA, Nannaji
IPC Classifications
A61K 9/00 20060101AFI20190717BHEP A61K 9/16 20060101ALI20190717BHEP A61K 31/167 20060101ALI20190717BHEP A61K 31/192 20060101ALI20190717BHEP A61K 9/20 20060101ALI20190717BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.